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doi:10.1016/j.ejvsextra.2008.11.002Abstract Cyclo-oxygenase-2 inhibitors are thought to be associated with an increased risk of
cardiovascular events as a result of alteration in hemostasis. We report the case of a 39-
year-old patient with minimal risk factors for cardiovascular disease who was prescribed
a cyclo-oxygenase-2 inhibitor. He presented with symptoms of distal vessel thrombosis which
was confirmed with angiography; this provides further evidence of the possible association of
cyclo-oxygenase-2 inhibitors and thrombus formation.
ª 2008 European Society for Vascular Surgery. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.Introduction
Recent clinical trials have demonstrated a possible increase
in cardiovascular events associated with cyclo-oxygenase-2
(COX-2) inhibitors. This is attributed to a disruption in
normal physiological hemostasis which contributes to
thrombus formation, an essential component in the path-
ophysiology of cardiovascular disease. In the following case
report, we present a case of peripheral thrombosis in
a young patient with minimal risk factors who was also
prescribed a COX-2 inhibitor.jvs.2008.11.020.
dra, 120 Stanks Drive, Leeds
mobile: þ7730619990.
t.uk (M. Chandra).
r Vascular Surgery. Published byCase Report
In August 2004, a 39-year-old man with longstanding
ulcerative colitis and associated arthritis, presented with
an 8-week history of pain in his right foot, which was worse
when walking and in cold environments. He had no major
risk factors for peripheral vascular disease other than total
cholesterol of 5.6 mmol/l. His medications included pred-
nisolone, mesalazine, calcichew and celecoxib which he
had been taking for two years prior to this presentation.
On examination, the right forefoot appeared pale with
evidence of venous guttering. Ankle brachial pressure index
readings were 1.1 bilaterally. A clinical diagnosis of distal
vessel occlusion was made.
An intra-arterial digital subtraction angiogram demon-
strated diseased vessels below the mid-calf of the right leg,Elsevier Ltd.Open access under CC BY-NC-ND license.
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arteries and a much attenuated posterior tibial artery
(Fig. 1).
It was commented upon that this was in keeping with
vascular disease secondary to a hypercoaguable state.
A cardiology review, which included an ECG and echocar-
diogram, concluded that there was no cardiac abnormality
or potential source of emboli. Thrombophilia screening,
cryoglobulins and immunoglobulin electrophoresis were all
negative; homocysteine levels were normal. A vasculitic
screen was positive for atypical p-ANCA and weakly positive
for ANA; other markers were negative.
The patient was treated with a 5-day course of prosta-
cyclin infusions which resulted in resolution of his
symptoms.
Discussion
Non-steroidal anti-inflammatory drugs (NSAIDs) have been
used effectively as both analgesic and anti-inflammatory
agents; however, they also demonstrate a significant
gastrointestinal side effect profile. The development of
more selective cyclo-oxygenase (COX) inhibitors has
provided a similar class of drug with a reduced gastroin-
testinal effect.1 However, over recent years, a variety of
clinical trials have highlighted a possible association with
COX-2 inhibitors and an increased risk of cardiovascular and
cerebrovascular events. While the Vioxx Gastrointestinal
Outcomes Research Study (VIGOR) compared the incidence
of gastrointestinal side effects of rofecoxib and naproxen in
patients with rheumatoid arthritis, results showed that theFigure 1 Intra-arterial digital subtraction angiogram of the right c
mid-calf.relative risk of developing a thrombotic cardiovascular
event with rofecoxib was 2.38 (95% confidence interval
1.39e4.00; pZ 0.002) compared to naproxen.2 A more
recent study, the Adenoma Prevention with Celecoxib
(APC), was discontinued due to the cardiovascular effects
observed.3 In this study 1% of patients in the placebo group
died from cardiovascular causes compared to 2.3%
receiving 200 mg celecoxib twice daily and 3.4% receiving
400 mg twice daily showing a dose related increase in
deaths from cardiovascular causes.
One proposed mechanism of the cardiovascular effect of
COX-2 inhibitors is the disruption of hemostasis which
occurs during vascular stimulation such as rupture of an
atheromatous plaque.4 In the vascular endothelium COX-2
is responsible for prostacyclin (PGI2) production, a prosta-
glandin which inhibits platelet aggregation and prolifera-
tion of vascular muscle cells while promoting
vasodilatation. Thromboxane A2 (TXA2), which is a major
product of platelet COX-1, promotes platelet aggregation,
vasoconstriction and vascular proliferation; in other words
the opposite effects of prostacyclin. During vascular stim-
ulation there is an increase in both PGI2 and TXA2 main-
taining hemostasis. However, when there is inhibition of
endothelial prostacyclin by a COX-2 inhibitor, the effects of
TXA2 predominate resulting in a prothrombotic state.
5
There have been reports of thrombosis in ulcerative
colitis; however, these have mainly been venous. Arterial
thrombi affecting aortoiliac, femoropopliteal, and digital
arteries have been reported but more commonly in Crohn’s
disease. These predominantly occur postoperatively or
during acute exacerbations.6alf and ankle showing occlusion of the distal arteries below the
16 M. Chandra, P.J. KentIn the absence of risk factors and given the young age of
the patient in this case, the presentation of peripheral
vascular symptoms could be attributed to COX-2 inhibitors.
The proposed mechanism of this association, namely an
induced prothrombotic state, was further implicated by the
angiographic findings.
In the majority of studies concerning COX-2 inhibitors
and cardiovascular disease, outcomes have included
myocardial infarction and stroke; however since there is
a similar underlying mechanism of thrombus formation, we
postulate that there may be an association between COX-2
inhibitors and peripheral thrombotic episodes. While there
have been no such cases reported in the literature, this
case report highlights such a possibility.
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